Alphatec (NASDAQ:ATEC) Posts Earnings Results, Meets Estimates

Posted by on Aug 5th, 2026

Alphatec (NASDAQ:ATEC – Get Free Report) announced its quarterly earnings results on Tuesday. The medical technology company reported $0.07 EPS for the quarter, meeting analysts’ consensus estimates of $0.07, FiscalAI reports. Alphatec had a negative net margin of 15.93% and a negative return on equity of 1,183.84%. The firm had revenue of $213.51 million during the quarter, compared to the consensus estimate of $211.26 million. During the same quarter last year, the firm earned $0.02 EPS. The firm’s revenue for the quarter was up 15.1% compared to the same quarter last year.

Here are the key takeaways from Alphatec’s conference call:

  • Q2 revenue rose 15% to $214 million, with surgical revenue up 17%, cases up approximately 20%, and net new surgeons up 24%, indicating continued adoption and utilization momentum.
  • Profitability improved significantly, with adjusted EBITDA up 53% year over year to $36 million and margin expanding to 17%; the company raised full-year adjusted EBITDA guidance to approximately $140 million from $134 million.
  • ATEC generated positive free cash flow for the quarter and expects $4 million-$6 million in Q3, while its refinanced credit facilities extend maturities to 2031 and are expected to reduce annual interest expense by more than $6 million.
  • Full-year revenue guidance remains unchanged at approximately $882 million, with high-teens surgical case growth expected in the second half; however, revenue per case is now expected to decline by low single digits, primarily because biologics attachment has stabilized below prior-year levels.
  • Management highlighted EOS, EOS Insight, Valence, and SafeOp as key growth catalysts, citing approximately 32% implant-revenue growth within six months of EOS Insight adoption and growing access to leading academic and deformity-focused institutions.

Alphatec Trading Up 2.0%

ATEC opened at $10.35 on Wednesday. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.12 and a current ratio of 1.90. The stock’s 50 day moving average price is $8.70 and its 200-day moving average price is $10.83. Alphatec has a one year low of $6.82 and a one year high of $23.29. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -12.62 and a beta of 0.85.

Insider Activity

In related news, Director Karen K. Mcginnis sold 6,050 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $8.01, for a total transaction of $48,460.50. Following the completion of the sale, the director directly owned 94,671 shares of the company’s stock, valued at approximately $758,314.71. This trade represents a 6.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 13.48% of the company’s stock.

Institutional Trading of Alphatec

A number of hedge funds and other institutional investors have recently bought and sold shares of ATEC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Alphatec by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,005 shares of the medical technology company’s stock worth $750,000 after purchasing an additional 3,196 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Alphatec in the first quarter worth about $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Alphatec by 18.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company’s stock worth $2,696,000 after buying an additional 41,264 shares during the period. Quantbot Technologies LP purchased a new position in Alphatec in the 2nd quarter worth about $242,000. Finally, Invesco Ltd. lifted its holdings in Alphatec by 455.0% during the 2nd quarter. Invesco Ltd. now owns 282,212 shares of the medical technology company’s stock valued at $3,133,000 after buying an additional 231,367 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ATEC. Needham & Company LLC lowered their price objective on Alphatec from $25.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. JPMorgan Chase & Co. cut their target price on Alphatec from $24.00 to $16.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. TD Cowen decreased their price target on Alphatec from $20.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Wells Fargo & Company dropped their price objective on shares of Alphatec from $28.00 to $14.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. Finally, Stephens started coverage on shares of Alphatec in a research note on Thursday, July 23rd. They issued an “overweight” rating and a $15.00 target price on the stock. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Alphatec currently has an average rating of “Moderate Buy” and a consensus price target of $17.20.

Get Our Latest Stock Analysis on ATEC

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.

Featured Stories

Earnings History for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.